20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT
Ref.: C.L.15.2026
The World Health Organization (WHO) presents its compliments to Member States and
Associate Members and has the honour to inform that WHO is initiating a consultation with its
Member States to review country estimates for the newly approved Sustainable Development
Goals (SDG) indicator on access to health products (SDG indicator 3.b.3 – Health Product
Access Index).
In March 2025, the United Nations Statistical Division approved the Health Product
Access Index as the replacement for the former SDG indicator 3.b.3 – Proportion of health
facilities that have a core set of relevant essential medicines available and affordable on a
sustainable basis. Modeled after SDG indicator 3.8.1 – Universal Health Coverage Service
Coverage Index, the Health Product Access Index is composite indicator that summarizes data
from a set of tracer indicators spanning access to medicines, vaccines, diagnostics, assistive
products, and other essential health products.
Member States are requested to nominate or confirm a technical focal point for this
consultation. Contact details (full name, title, affiliation, and e-mail address) should be submitted
no later than 27 May to WHO’s Department of Health Products Policies and Standards via
[email protected]. If focal points have been previously designated for other SDG health indicators,
Member States are invited to either confirm the same focal point(s) or designate a new one for
this indicator.
The nominated focal point(s) may also be asked to review draft indicator values for future
indicators related to medicines and health products access, as WHO continues to develop and
refine global indicators related to the monitoring of access to medicines and health products.
WHO suggests that Member States designate a focal point who has expertise or experience
in one or more of the following areas:
1) Health service coverage monitoring, including experience with population-based health
surveys, routine health information systems, and administrative data sources that provide
information on the coverage of health services and health product use.
2) Access to medicines and health products, including supply chain monitoring,
procurement data, or regulatory policy.
Documentation of methods, data sources, and preliminary country estimates will be shared
with designated focal points beginning 1 June. Focal points will have three months to review
these materials and, where applicable, to provide additional national data needed to produce or
validate indicator values. Submissions received after this date may not be incorporated into the
final publication of country estimates. Any questions about the process may be addressed by
email to
[email protected].
Page 2
C.L.15.2026
Following the country consultation, WHO will release global, regional, and country-level
estimates of SDG indicator 3.b.3 on its website as well as on the United Nations Statistics
Division’s SDG global data portal. The estimates will be featured in future global health
products access monitoring reports.
The World Health Organization takes this opportunity to renew to Member States and
Associate Members the assurance of its highest consideration.
GENEVA, 21 April 2026
Saatja: "ola" <
[email protected]>
Teema: C.L.15.2026 (Country estimates for newly approved SDGs)
Kuupäev: 2026-04-21 11:57
Tähelepanu! Tegemist on välisvõrgust saabunud kirjaga.
Tundmatu saatja korral palume linke ja faile mitte avada. Dear
Member States of the World Health Organization,
Please find attached, in the six official languages, C.L.15.2026 informing
that WHO is initiating a consultation with its Member States to review
country estimates for the newly approved Sustainable Development Goals
(SDG) indicator on access to health products (SDG indicator 3.b.3 – Health
Product Access Index).
For any further information, please contact
[email protected].
Best regards,
Department of Governing Bodies
World Health Organization
***DO NOT RESPOND TO THIS E-MAIL. YOU WILL NOT RECEIVE A REPLY***